Previous 10 | Next 10 |
2023-11-09 09:57:02 ET Verrica Pharmaceuticals Inc. (VRCA) Q3 2023 Earnings Conference Call November 09, 2023 08:30 AM ET Company Participants Kevin Gardner - LifeSci Advisors Ted White - President & Chief Executive Officer\ Joe Bonaccorso - Chief Commercial ...
2023-11-09 07:36:56 ET More on Verrica Pharmaceuticals Seeking Alpha’s Quant Rating on Verrica Pharmaceuticals Historical earnings data for Verrica Pharmaceuticals Financial information for Verrica Pharmaceuticals For further details see: Verrica P...
– Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Verrica Pharmaceuticals Inc. (VRCA) is expected to report $-0.22 for Q3 2023
WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host...
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will hos...
WEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that that Ted Whi...
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children FFF Enterprises is Verrica’s exclusive distribution partner for YCANTH...
Verrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH™ is expected to be available for commerci...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...